The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has
been a major focus of oncology research. The p53 protein is a transcription factor that can …

In today's modern era of medicine, macromolecular compounds such as proteins, peptides
and nucleic acids are dethroning small molecules as leading therapeutics. Given their …

The presence of cell and tissue barriers together with the low biomembrane permeability of
various therapeutics often hampers systemic drug distribution; thus, most of the available …

Cell-penetrating-peptides (CPPs) are small amino-acid sequences characterized by their
ability to cross cellular membranes. They can transport various bioactive cargos inside cells …

With more than ten new FDA approvals since 2001, peptides are emerging as an important
therapeutic alternative to small molecules. However, unlike small molecules, peptides on the …

Efficient intracellular trafficking and targeted delivery to the site of action are essential to
overcome the current drawbacks of cancer therapeutics. Cell Penetrating Peptides (CPPs) …

The plasma membrane as a selectively permeable barrier of living cells is essential to cell
survival and function. In many cases, however, the efficient passage of exogenous bioactive …

In the field of nanotherapeutics, gaining cellular entry into the cytoplasm of the target cell
continues to be an ultimate challenge. There are many physicochemical factors such as …

Alzheimer's disease (AD) will affect around 115 million people worldwide by the year 2050.
It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and …

The failure of proteins to penetrate mammalian cells or target tumor cells restricts their value
as therapeutic tools in a variety of diseases such as cancers. Recently, protein transduction …